Pfizer's Inlyta gets NICE nod, but Dendreon's Provenge doesn't; Lilly chief maintains stance against megamergers;

@FiercePharma: ICYMI yesterday: Serum Institute and Bharat Biotech race to get swine flu vaccines back on the market. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: In case you missed our newest special: Top 10 drug brands by payments to doctors. Report | Follow @CarlyHFierce

> Pfizer's ($PFE) kidney cancer drug Inlyta won backing from British cost-effectiveness watchdogs, but Provenge, the Dendreon ($DNDN) med recently purchased by Valeant Pharmaceuticals ($VRX), wasn't so lucky. Report

> Eli Lilly ($LLY) CEO John Lechleiter maintains that big mergers are bad for pharma companies, and says he believes Lilly is immune to a hostile takeover. Report

> British doctors called on health officials to favor off-label use of the Roche ($RHHBY) cancer drug Avastin as an eye treatment, over the more expensive Lucentis, marketed in Europe by Novartis ($NVS). Report

> Biosimilar versions of the top-selling anti-inflammatory Remicade have rolled out in Europe. Report

Medical Device News

@FierceMedDev: Reuters: Boston Scientific close to $2B deal for Endo's AMS device unit. Report | Follow @FierceMedDev

@VarunSaxena2: From my med tech M&A special report: Zimmer swallowing up Biomet, leading to chain of other deals. More | Follow @VarunSaxena2

@EmilyWFierce: Get this week's ed. of FierceDiagnostics here, feat. 23andMe, $RHHBY and a new collaboration for Alzheimer's Dx. Newsletter | Follow @EmilyWFierce

> FDA in midst of updating endoscope labels implicated in 'superbug' infections. Report

> FDA weighs in on Intuitive Surgical recall of da Vinci vessel sealer due to inadequate grasping. More

Biotech News

@FierceBiotech: Little Neos gets a $20M bankroll to prep ADHD drugs for FDA review. News | Follow @FierceBiotech

@JohnCFierce: Top 10 drug brands by payments to doctors, from the FiercePharma Marketing team. Special report | Follow @JohnCFierce

@DamianFierce: Hey so @FierceBiotech has a podcast now, and you can listen online. Listen | Follow @DamianFierce

> Can Neil Woodford reignite the U.K.'s taste for biotech investments? More

> Takeda's betting on its pipeline to spur a long-awaited turnaround. Item

> Hospira and Celltrion storm the EU with biosimilars of J&J's Remicade. Article

Drug Delivery News

> OncoSec's intratumoral delivery platform to be tested on new partner's cancer candidates. Report

> MIT team injects drug-carrying hydrogel that 're-heals' in the body. Story

> WHO adopts new safety needle policy, calling smart syringes an 'urgent priority.' Article

> Prometheon touts its transdermal delivery system for large molecules, prepares to launch hair growth gel. Item

> FDA agrees to review Endo Pharmaceutical's inside-the-cheek pain drug. News

Diagnostics News

> Israeli colon capsule maker reels in $24M in IPO and private placement. More

> Roche, BioMed X to jointly run diagnostics incubator in Germany. Article

> Foundation Medicine rides tailwinds of successful Q4 2014. Item

> Department of Defense gives contractor $14.8M to test so-called Sample-to-Sequence system. Report

> 23andMe scores FDA OK to market genetic carrier test direct to consumers. News

Pharma Marketing News

> Can Pfizer's new breast cancer med really cruise to $4B and beyond? Article

> Shire's Vyvanse brand team draws fire for aggressive binge-eating push. More

> British doctors lobby NHS to use cheap Avastin over Lucentis in AMD. Report

> With peglispro shunted aside, Lilly could go full-tilt after Lantus. Story

> Valeant to keep specialty Salix reps, but it's eyeing primary care for potential cuts. Article

And Finally... A study that paid patients to take their HIV meds essentially failed, scientists said. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.